US Bancorp DE reduced its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 2.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,405 shares of the biopharmaceutical company’s stock after selling 923 shares during the quarter. US Bancorp DE’s holdings in Alexion Pharmaceuticals were worth $4,637,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC bought a new stake in shares of Alexion Pharmaceuticals in the second quarter valued at about $28,000. Redhawk Wealth Advisors Inc. purchased a new position in Alexion Pharmaceuticals in the second quarter valued at about $29,000. Ossiam purchased a new position in Alexion Pharmaceuticals in the second quarter valued at about $32,000. Thor Advisors LLC purchased a new position in Alexion Pharmaceuticals in the first quarter valued at about $34,000. Finally, NEXT Financial Group Inc purchased a new position in Alexion Pharmaceuticals in the second quarter valued at about $36,000. Hedge funds and other institutional investors own 93.13% of the company’s stock.

Shares of ALXN stock traded up $2.80 during trading hours on Thursday, reaching $105.78. 65,020 shares of the company’s stock were exchanged, compared to its average volume of 3,228,866. Alexion Pharmaceuticals, Inc. has a 1 year low of $92.56 and a 1 year high of $141.86. The stock has a market cap of $24.34 billion, a PE ratio of 14.89, a PEG ratio of 1.03 and a beta of 1.67. The company has a current ratio of 4.04, a quick ratio of 3.56 and a debt-to-equity ratio of 0.26. The stock’s fifty day moving average price is $109.08 and its two-hundred day moving average price is $123.85.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.51. Alexion Pharmaceuticals had a return on equity of 20.23% and a net margin of 29.64%. The business had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same quarter in the previous year, the firm earned $2.07 earnings per share. The company’s revenue was up 15.1% on a year-over-year basis. On average, equities analysts expect that Alexion Pharmaceuticals, Inc. will post 9.03 EPS for the current fiscal year.

In other news, insider Aradhana Sarin sold 578 shares of the business’s stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $132.00, for a total transaction of $76,296.00. Following the sale, the insider now owns 30,201 shares in the company, valued at $3,986,532. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Indrani Lall Franchini sold 4,500 shares of Alexion Pharmaceuticals stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $132.78, for a total value of $597,510.00. Following the sale, the executive vice president now directly owns 29,627 shares of the company’s stock, valued at approximately $3,933,873.06. The disclosure for this sale can be found here. 4.08% of the stock is currently owned by insiders.

ALXN has been the topic of several analyst reports. Morgan Stanley set a $177.00 target price on Alexion Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 21st. Robert W. Baird set a $165.00 target price on Alexion Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 30th. Goldman Sachs Group reiterated a “neutral” rating and issued a $142.00 target price on shares of Alexion Pharmaceuticals in a research note on Thursday, May 23rd. Credit Suisse Group cut their target price on Alexion Pharmaceuticals from $154.00 to $146.00 and set an “outperform” rating on the stock in a research note on Friday, September 6th. Finally, Citigroup set a $150.00 target price on Alexion Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 30th. One analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $160.44.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Article: The Structure of a Futures Contract

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.